Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.95 |
| ▸ | GMNN | O75496 | 1/20 | 0.95 |
| ▸ | LMNA | P02545 | 1/20 | 0.95 |
| ▸ | MAPT | P10636 | 1/20 | 0.95 |
| ▸ | BLM | P54132 | 1/20 | 0.95 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.95 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.95 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SHBG | P04278 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL133228 | 1.00 | TP53 (1.00) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL23270700 | 1.00 | TP53 (1.00) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL5228082 | 1.00 | TP53 (1.00) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL4079339 | 1.00 | TP53 (1.00) | TP53KDM4EGMNNLMNAMAPT | |
| Hydrochloric Acid SCHEMBL160732 | 0.97 | KDM4E (1.00) | TP53KDM4EGMNNLMNAMAPT | |
| Hydrochloric Acid SCHEMBL2063394 | 0.97 | KDM4E (1.00) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL3647508 | 0.97 | — | — | |
| SCHEMBL22535894 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL19642704 | 0.95 | KDM4E (0.95) | TP53KDM4EGMNNLMNAMAPT | |
| Hydrochloric Acid SCHEMBL30187467 | 0.95 | KDM4E (0.95) | TP53KDM4EGMNNLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482339-B2 | 2-Naphthylimino-1,3-thiazine derivative | SHIONOGI AND CO., LTD. (JP) | 2009-01-27 | — | — | US | disclosed |
| EP-1844003-A1 | NOVEL BIAROMATIC COMPOUNDS, INHIBITORS OF THE P2X7-RECEPTOR | AstraZeneca AB (SE) | 2007-10-17 | — | — | EP | disclosed |
| US-20060281738-A1 | 2-Naphthylimino-1,3-thiazine derivative | SHIONOGI AND CO., LTD. (JP) | 2006-12-14 | — | — | US | disclosed |
| WO-2006080884-A1 | NOVEL BIAROMATIC COMPOUNDS, INHIBITORS OF THE P2X7-RECEPTOR | ASTRAZENECA AB (SE) | 2006-08-03 | — | — | WO | disclosed |
| EP-1659117-A1 | 2-NAPHTHYLIMINO-1,3-THIAZINE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2006-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281738-A1 | 2-Naphthylimino-1,3-thiazine derivative | NPM1, OXTR, CYP2S1 | TP53 1572/4885KDM4E 4479/4885GMNN 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.